You are here

Home » Content

Sürekli Ayaktan Periton Diyalizi Hastalarında Kalan Böbrek İşlevlerine Biyouyumlu Solüsyonların Etkisi: Prospektif Gözlemsel Bir Çalışma

Effects of Biocompatible Solutions on Residual Renal Functions in Peritoneal Dialysis Patients: A Prospective Observational Study

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2011
DOI: 
DOI 10.5262/tndt.2011.1001.05

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
OBJECTIV E: Residual renal function (RRF) is an important predictor of patient and dialysis technique survival in both hemodialysis (HD) and peritoneal dialysis (PD). Although there have been some studies conducted recently about the relationship between RRF and standard or biocompatible PD solutions; results are conflicting. Therefore, we aimed to conduct a prospective observational study comparing patients using standard PD solutions with those using biocompatible ones in terms of RRF. MA TERIAL and M ETHODS: Adult PD patients treated for more than three months with daily four times two-liter dwells were included. Patients using standard lactate-based PD solution (Dianeal 1.36%) were called Group-1; and those using biocompatible PD solution (Physioneal 1.36%) Group- 2. The patients’ body weight, total ultrafiltration, residual urine volume, blood count, biochemical parameters and standard PET results were recorded every three months for a year. Statistical analysis was performed by SPSS for Windows ver.13.0. RESUL TS: The groups were similar regarding demographic and biochemical parameters except gender. Serum urea levels at 9th and 12th months were lower in Group-2. Residual urine output decreased in both groups with the decrease more prominent in Group-1 although not statistically significant. CONCLU SION: Biocompatible PD solutions may protect RRF more than standard solutions. However, there is need for randomized prospective controlled studies with larger population of patients about the morbidity and mortality.
Bookmark/Search this post with
Abstract (Original Language): 
AMA Ç: Hemodiyaliz (HD) ve periton diyalizinde (PD) hastanın ve diyaliz tekniğinin sağkalımı açısından kalan böbrek işlevleri (KBİ) önemli bir belirleyicidir. Son zamanlarda standart ve biyouyumlu PD solüsyonları ile KBİ arasındaki ilişkiyi irdeleyen bazı çalışmalar yapılmasına karşın sonuçlar birbiriyle uyuşmamaktadır. Bu nedenle standart solüsyonları kullanan sürekli ayaktan periton diyalizi (SAPD) hastalarıyla biyouyumlu solüsyonları kullanan hastaları KBİ açısından karşılaştıran prospektif bir gözlem çalışması yapmayı amaçladık. GEREÇ ve YÖN TEML ER: Üç aydan daha uzun zamandır ve sadece günde dört defa 2 litre ile değişim yapan PD hastaları çalışmaya alındı. Standart laktat bazlı PD solüsyonu (Dianeal %1,36) kullananlar Grup 1, biyouyumlu PD solüsyonu (Physioneal %1,36) kullananlar Grup 2 olarak adlandırıldı. Hastaların vücut ağırlığı, toplam ultrafiltrasyonu, idrar miktarı, tam kan sayımı, biyokimyasal parametreleri, 12 aylık çalışma süresi boyunca her 3 ayda bir ve standart PET testleri kaydedildi. İstatistiksel analizlerde SPSS for Windows ver. 13.0 paket programı kullanıldı. BUL GULA R: Cinsiyetler dışında gruplar demografik ve biyokimyasal değerler olarak benzerdi. Dokuz ve 12. aylarda serum üre düzeyleri Grup 2’de daha düşüktü. Her iki grupta da rezidüel idrar miktarı zamanla azaldı; bu azalma Grup-1’de daha fazla olmasına rağmen fark istatistiki olarak anlamlı değildi. SONU Ç: Biyouyumlu PD solüsyonları KBİ’yi standart solüsyonlardan daha iyi koruyabilir. Ancak mortalite ve morbiditenin araştırıldığı, daha çok sayıda hastayla randomize kontrollü prospektif çalışmalar yapılmalıdır
FULL TEXT (PDF): 
PDF icon arastrmx_172977_20_pp_26-31.pdf
  • 1
26-31
  • Turkish

REFERENCES

References: 

1. K/DOQI practice guidelines for chronic kidney disease: Evaluation,
classification and stratification. Kidney Disease Outcome Quality
Initiative. Am J Kidney Dis 2002; 39: 1-246
2. Levey AS, Coresh C, Balk E, Kausz AT, Levin A, Steffes MW, Hogg
RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation
Practice Guidelines for Chronic Kidney Disease: Evaluation,
Classification, and Stratification. Ann Intern Med 2003; 139:
137-147
3. Türk Nefroloji Derneği, 2008 Registry Raporu: http://tsn.org.tr/
folders/file/registry%20kitap.pdf.
4. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized
controlled study of biocompatible peritoneal dialysis solutions:
Effect on residual renal function. Kidney Int 2008; 73: 200-206
5. Termorshuizen F, Dekker FW, van Mannen JG, Korevaar JC,
Boeschoten EW, Krediet RT: NECOSAD Study Group. Relative
contribution of residua renal function and different measures of
adequacy to survival in hemodialysis patients: An analysis of
the Netherlands Cooperative Study on the Adequacy of Dialysis
(NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061-1070
6. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of
residual renal function and peritoneal clearance on adequacy of
dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol
2001; 12: 2158-2168
7. McKane W, Chandna SM, Tattersall JE, Greenwood RN,
Farrington K: Identical decline of residual renal function in highflux
biocompatible hemodialysis and CAPD. Kidney Int 2002; 61:
256-265
8. Altıntepe L, Güney İ, Türk S, Tonbul HZ, Yeksan M: Hemodiyaliz
ve sürekli ayaktan periton diyalizi hastalarında yaşlam kalitesi ve
etkileyen faktörler. Turk Neph Dial Transpl 2005; 14(2): 85-89
9. Ateş K: Periton diyalizi ve rezidüel böbrek fonksiyonu. Turk Neph
Dial Transpl 2007; 16(2): 12-20
10. Twardowski ZJ: Tidal peritoneal dialysis. In: Nissenson AR, Fine
RN (eds), Dialysis Therapy. Philadelphia: Hanley&Belfius 2002;
225-228
11. Burkart JM, Daeihagh P, Rocco MV: Peritoneal Dialysis. In: Brenner
BM (ed), Brenner and Rector’s The Kidney. Philadelphia: Saunders
2004; 2625-2695
12. Twardowski ZJ: Tidal periton diyalizi. Ateş K. (çev), In: Diyaliz
Tedavisi, Nissenson AR, Fine RN,(eds), Süleymanlar G, Erek E
(Çeviri Editörleri), (3.Bsk), Ankara: Güneş kitabevi, 2004; 225-239
13. Kathuria P, Twardowski ZI: Automated peritoneal dialysis. In:
Gokal R, Krediet R, Nolph K (eds), Textbook of Peritoneal Dialysis.
Dordrectht: Kluwer Academic Publishers, 2000; 435-463
14. Duranay M, Yılmaz FM, Parpucu H, Yücel D: Aminoasit bazlı diyaliz
solüsyonunun hipoalbüminemik periton diyalizi hastalarında
biyokimyasal etkileri. Turk Neph Dial Transpl 2005; 14(3): 127-131
15. Bakkaloğlu SA: Yeni periton diyalizi solüsyonları. Turk Neph Dial
Transpl 2001; 10(3): 134-139
16. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim
YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK: Superior patient
survival for continuous ambulatory peritoneal dialysis patients
treated with a peritoneal dialysis fluid with neutral pH and low
glucose degradation product concentration (Balance). Perit Dial Int
2005; 25: 248-255
17. Locatelli F, La Milia V: Preservation of residual renal function in
peritoneal dialysis patients: still a dream? Kidney Int 2008; 73:
143-145. Comment on: Kidney Int 2008; 73 (2): 200-206
18. Twardowski ZJ, Nolph KO, Khanna R, Prowant BF, Ryan LP,
Moore HL and Nielsen MP. Peritoneal Equilibration Test. Perit Dial
Int 1987; 7: 138-148
19. Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Erturk S, Duman N,
Karatan O, Ertuğ AE: Effect of fluid and sodium removal on mortality
in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776
20. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, Li
PK: Important differentiation of factors that predict outcome in
peritoneal dialysis patients with different degrees of residual renal
function. Nephrol Dial Transplant 2005; 20: 396-403
21. Szeto CC, Wong TY, Chow KM, Leung CB, Law MC, Li PK:
Independent effects of renal and peritoneal clearances on the mortality
of peritoneal dialysis patients. Perit Dial Int 2004; 24: 58-64
22. Wang AY, Lam JW, Wang M, Woo J, Chan IH, Lui SF, Sandeson
JE, Li PK: Circulating soluble vascular cell adhesion molecule 1:
Relationships with residual renal function, cardiac hypertrophy and
outcome of peritoneal dialysis patients. Am J Kidney Dis 2005; 45:
715-729
23. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm
B: Association between inflammation and changes in residual
renal function and peritoneal transport rate during the first year of
dialysis. Nephrol Dial Transplant 2001; 16: 2240-2245
24. Kuno T, Matsumoto K: Clinical benefit of preserving residual renal
function in patients after initiation of dialysis. Blood Purif 2004; 22:
67-71
25. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an
angiotensin-converting enzyme inhibitor on residual renal function
in patients receiving peritoneal dialysis. A randomized, controlled
study. Ann Intern Med 2003; 139: 105-112
26. Jing S, Kezhou Y, Hong Z, Qun W, Rong W: Effect of reninangiotensin
system inhibitors on prevention of peritoneal fibrosis in
peritoneal dialysis patients. Nephrology (Carlton) 2010; 15: 27-32
27. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos
DG: Comparison between bicarbonate/lactate and standard dialysis
solution in peritoneal transport and ultrafiltration: A prospective,
crossover single-dwell study. Perit Dial Int 2008; 28: 35-43
28. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M,
Lage C, Passlick-Deetjen J, Euro Balance Trial Group: The effect
of a new biocompatible peritoneal dialysis fluid (balance) on the
peritoneal membrane. Kidney Int 2004; 66: 408-418
29. Montenegro J, Saracho RM, Martínez IM, Muñoz RI, Ocharan JJ,
Valladares E: Long-term clinical experience with pure bicarbonate
peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94
30. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH: Benefits
of biocompatible PD fluid for preservation of residual renal function
in incident CAPD patients: A 1-year study. Nephrol Dial Transplant
2009; 24: 2899-2908

Thank you for copying data from http://www.arastirmax.com